Lv4
460 积分 2024-04-02 加入
Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
9个月前
已完结
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions
9个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
10个月前
已完结
Letter: Drug interaction in resmetirom times
10个月前
已完结
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
10个月前
已完结
Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics
10个月前
已完结
Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis
10个月前
已完结
Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States
10个月前
已完结
皖公网安备34019202002308
